[Form 5] GALECTIN THERAPEUTICS INC Annual Statement of Beneficial Ownership

Filing Impact

(Low)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Galectin Therapeutics (GALT) filed a Form 5

The reporting person is marked as a Director, with holdings reported as indirect through 10X Fund, L.P. The disclosure notes that 10X Capital Management, LLC is the general partner of 10X Fund, L.P. and may be deemed to have indirect beneficial ownership, while disclaiming beneficial ownership except to the extent of pecuniary interest.

Galectin Therapeutics (GALT) ha presentato un Modulo 5 riportando cambiamenti nella proprietà degli insider per l'anno chiuso al 31/12/2024. La pratica mostra transazioni indirette da parte del 10X Fund, L.P. in due date: la vendita di 21.323 azioni il 22/04/2024 a 3,06$ per azione, e la vendita di 3.677 azioni il 23/04/2024 a 3,06$ per azione.
La persona che segnala è contrassegnata come Direttore, con le partecipazioni riportate come indirette tramite 10X Fund, L.P. La pubblicazione nota che 10X Capital Management, LLC è il socio generale di 10X Fund, L.P. e potrebbe essere ritenuto detentore di proprietà indiretta, pur dichiarando di non possedere una proprietà benefica eccetto che per l'interesse pecuniario.

Galectin Therapeutics (GALT) presentó un Formulario 5 informando cambios en la propiedad de insiders para el año terminado el 31/12/2024. La presentación muestra transacciones indirectas por parte de 10X Fund, L.P. en dos fechas: una venta de 21,323 acciones el 22/04/2024 a 3,06 dólares por acción, y una venta de 3,677 acciones el 23/04/2024 a 3,06 dólares por acción.
La persona reportante figura como Director, con participaciones reportadas como indirectas a través de 10X Fund, L.P. La divulgación señala que 10X Capital Management, LLC es el socio general de 10X Fund, L.P. y podría considerarse que tiene propiedad beneficiosa indirecta, mientras se niega la propiedad beneficiosa salvo en la medida de interés pecuniario.

Galectin Therapeutics (GALT)가 Form 5를 제출했습니다 지난 2024년 12월 31일로 종료되는 연도에 대한 내부자 소유 변화 보고입니다. 신고서는 10X Fund, L.P.가 두 건의 날짜에 간접 거래를 했음을 보여주며: 2024년 4월 22일 주당 3.06달러로 21,323주 판매, 2024년 4월 23일 주당 3.06달러로 3,677주 판매.
신고자는 이사로 표시되며 지분은 간접으로 10X Fund, L.P.를 통해 보고됩니다. 공시는 10X Capital Management, LLC가 10X Fund, L.P.의 일반 파트너이며 간접적인 유익 소유권을 가질 수 있다고 보이지만, 재산적 이해관계의 범위 내에서만 유익 소유권을 주장하지 않는다고 명시합니다.

Galectin Therapeutics (GALT) a déposé un Formulaire 5 signalant des changements de propriété des initiés pour l'année se terminant le 31/12/2024. Le dépôt montre des transactions indirectes par le 10X Fund, L.P. à deux dates: une vente de 21 323 actions le 22/04/2024 à 3,06 $ par action, et une vente de 3 677 actions le 23/04/2024 à 3,06 $ par action.
La personne déclarant est indiquée comme Directeur, les participations étant signalées comme indirectes via 10X Fund, L.P. La divulgation note que 10X Capital Management, LLC est le partenaire général de 10X Fund, L.P. et peut être considéré comme détenant une propriété bénéficiaire indirecte, tout en déclinant toute propriété bénéficiaire sauf dans la mesure de l'intérêt financier.

Galectin Therapeutics (GALT) hat ein Formular 5 eingereicht und meldet Änderungen des Insiderbesitzes für das Jahr, das am 31.12.2024 endete. Die Einreichung zeigt indirekte Transaktionen durch 10X Fund, L.P. an zwei Terminen: einen Verkauf von 21.323 Aktien am 22.04.2024 zu 3,06 USD pro Aktie und einen Verkauf von 3.677 Aktien am 23.04.2024 zu 3,06 USD pro Aktie.
Die meldende Person ist als Direktor gekennzeichnet, mit Beteiligungen, die als indirekt durch 10X Fund, L.P. gemeldet werden. Die Offenlegung vermerkt, dass 10X Capital Management, LLC der General Partner von 10X Fund, L.P. ist und als indirekt begünstigter Eigentümer gelten könnte, während behauptet wird, dass kein begünstigtes Eigentum besteht, außer dem finanziellen Interesse.

Galectin Therapeutics (GALT) قد قدمت نموذج 5، وتقرير عن تغييرات في ملكية الداخلين للسنة المنتهية في 31/12/2024. يُظهر التقرير معاملات غير مباشرة من 10X Fund, L.P. في تاريخين: بيع 21,323 سهماً في 22/04/2024 بسعر 3.06 دولار للسهم، وبيع 3,677 سهماً في 23/04/2024 بسعر 3.06 دولار للسهم.
المبلغ عنه مُشار إليه ك مدير، مع حيازات مُبلغ عنها كـ غير مباشرة عبر 10X Fund, L.P. وت notes أن 10X Capital Management, LLC هي الشريك العام لـ 10X Fund, L.P. وقد يُعتبر امتلاكاً غير مباشر للمستفيد، مع نفي وجود ملكية مستفيدة باستثناء المصلحة المالية.

Galectin Therapeutics (GALT) 已提交 Form 5，报告截至 2024 年 12 月 31 日的年度内部人持股变化。该披露显示由 10X Fund, L.P. 在两个日期进行的间接交易：2024/04/22 以每股 3.06 美元出售 21,323 股，及 2024/04/23 以每股 3.06 美元出售 3,677 股。
报告人被标记为董事，持股通过间接方式通过 10X Fund, L.P. 报告。披露指出，10X Capital Management, LLC 是 10X Fund, L.P. 的普通合伙人，可能被视为间接实益所有权的拥有者，同时声称除金钱利益外不享有实益所有权。

Positive

None.

Negative

None.

10/10/2025 - 06:27 PM

SEC Form 5

FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0362

Estimated average burden

hours per response: 1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported.

Form 4 Transactions Reported.

1. Name and Address of Reporting Person^*
10X Fund, L.P.

(Last) (First) (Middle)

545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)
ATLANTA, GA 30324

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director X 10% Owner

Officer (give title below) Other (specify below)

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
12/31/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Amount (A) or (D) Price

Common Stock 04/22/2024 S 21,323 D $3.06 5,925,884 I⁽¹⁾ By 10X Fund, LP

Common Stock 04/23/2024 S 3,677 D $3.06 5,922,207 I⁽¹⁾ By 10X Fund, LP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)

(A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

1. Name and Address of Reporting Person^*
10X Fund, L.P.

(Last) (First) (Middle)

545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)
ATLANTA, GA 30324

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

Director X 10% Owner

Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person^*
10X Capital Management, LLC

(Last) (First) (Middle)

545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)
ATLANTA, GA 30324

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

Director X 10% Owner

Officer (give title below) Other (specify below)

Explanation of Responses:

1. 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP 10/10/2025

/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC 10/10/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

[Form 5] GALECTIN THERAPEUTICS INC Annual Statement of Beneficial Ownership

NASDAQ:GALT

GALT Rankings

GALT Latest News

GALT Latest SEC Filings

GALT Stock Data

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/22/2024		S	21,323	D	$3.06	5,925,884	I⁽¹⁾	By 10X Fund, LP
Common Stock	04/23/2024		S	3,677	D	$3.06	5,922,207	I⁽¹⁾	By 10X Fund, LP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

	/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP	10/10/2025
	/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Trending News

[Form 5] GALECTIN THERAPEUTICS INC Annual Statement of Beneficial Ownership

NASDAQ:GALT

GALT Rankings

GALT Latest News

GALT Latest SEC Filings

GALT Stock Data